{
  "docId": "019de073-79f3-7749-b6d9-2feecaaa4d92",
  "docSlug": "3bbd721bd246637706dab09d5c4f3165",
  "documentTitle": "Apexigen | Investor Presentation Deck | 27 slides",
  "authorId": "apexigen",
  "authorName": "Apexigen",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 27,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 10,
  "notes": "Spider plot (swimmer plot variant) showing individual patient tumor response trajectories.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-79f3-7749-b6d9-2feecaaa4d92/19",
  "deckHref": "/decks/019de073-79f3-7749-b6d9-2feecaaa4d92",
  "deckJsonHref": "/decks/019de073-79f3-7749-b6d9-2feecaaa4d92.json",
  "deckAnchorHref": "/decks/019de073-79f3-7749-b6d9-2feecaaa4d92#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.75,
        "y": 0.3
      },
      "kind": "callout",
      "text": "Significant Clinical Benefit of Sotiga + Dox Combo: Durable PRs + SDs",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee595ff1-44b9-4892-a942-6398685b84c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.5,
        "x": 0.25,
        "y": 0.25
      },
      "kind": "chart",
      "text": "INTERIM DURATION OF RESPONSE",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb29fe0d-73db-4ae9-9d34-eda10b586448",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.3,
        "y": 0.85
      },
      "kind": "metric",
      "text": "Next Milestone: Fully Enroll P2 in H2 2022",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46bd0105-9d49-4eea-9525-f9fb43065b99",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.05,
        "y": 0.4
      },
      "kind": "paragraph",
      "text": "High Unmet Need: Single-agent doxorubicin SOC for decades; Cumulative cardiac toxicity limits dox dosing; Few new treatments.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7aeb8f06-c513-4563-b62f-ee5efa2f7251",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Data snapshot from Jan 2022: N=20 enrolled and evaluable.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ddde397d-69d7-48ce-be8d-fafe605f3350",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Ongoing Phase 2: Durable Responses to Sotigalimab-Doxorubicin Combination",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f506a325-a245-48a0-ab9c-db1d14bcef1c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "e4ecff01-7e89-470e-812c-dc9072863aa6",
      "evidence": "chart/line: INTERIM DURATION OF RESPONSE",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 12,
      "beatId": "3b7829c3-3966-42d3-a835-880f62f71399",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Slides 12-20 present various traction metrics, including clinical trial results and partnerships",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}